Seeyond’s Bio-Rad Laboratories Class A BIO Stock Holding History

Seeyond’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.49M	Sell	3,546 -373	-10%	-$151K	0.14%	204
2022 Q3	$1.63M	Sell	3,919 -209	-5%	-$104K	0.2%	144
2022 Q2	$2.04M	Sell	4,128 -82	-2%	-$42.7K	0.23%	129
2022 Q1	$2.37M	Buy	4,210 +725	+21%	+$437K	0.24%	119
2021 Q4	$2.63M	Hold	3,485	–	–	0.24%	106
2021 Q3	$2.6M	Sell	3,485 -734	-17%	-$550K	0.25%	105
2021 Q2	$2.72M	Buy	4,219 +19	+0.5%	+$11.6K	0.25%	96
2021 Q1	$2.4M	Hold	4,200	–	–	0.24%	113
2020 Q4	$2.45M	Sell	4,200 -691	-14%	-$394K	0.25%	102
2020 Q3	$2.52M	Sell	4,891 -381	-7%	-$193K	0.27%	83
2020 Q2	$2.38M	Buy	5,272 +3,087	+141%	+$1.36M	0.27%	85
2020 Q1	$845K	Sell	2,185 -17	-0.8%	-$6.25K	0.12%	251
2019 Q4	$815K	Buy	+2,202	New	+$776K	0.09%	374

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Seeyond's BIO Position: Q4 2022 in Review

Seeyond reduced its Bio-Rad Laboratories Class A (BIO) stake by 9.5% in Q4 2022, selling an estimated $151K and leaving 3,546 shares worth $1.49M. The position accounts for 0.14% of the portfolio, ranked #204.

Seeyond first reported a position in BIO in Q4 2019 and has held it in 13 quarters since. The position peaked at $2.72M in Q2 2021. 471 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

Seeyond held 3,546 shares of Bio-Rad Laboratories Class A worth $1.49M as of Q4 2022.
Seeyond sold 373 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $151K.
Bio-Rad Laboratories Class A made up 0.14% of Seeyond's portfolio in Q4 2022, its #204 holding.
Seeyond first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and has held it in 13 quarters since.
Seeyond's Bio-Rad Laboratories Class A position peaked at $2.72M in Q2 2021.
471 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Seeyond's 13F filing for Q4 2022, filed 13 Feb 2023.